All patients
Age < 65y (younger) Age > 65y Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mNSCLC - L1 - PDL1 positive, durvalumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
0.76 [0.56 ; 1.03 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 325 NA not evaluable progression or deaths (PFS)detailed results MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
0.87 [0.59 ; 1.29 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 325 NA not evaluable objective responses (ORR)detailed results MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
0.91 [0.58 ; 1.43 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 325 NA not evaluable AE (any grade)detailed results MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
0.42 [0.14 ; 1.22 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable AE (grade 3-4)detailed results MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
0.91 [0.58 ; 1.41 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable AE leading to death (grade 5)detailed results MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
0.75 [0.20 ; 2.86 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
0.75 [0.38 ; 1.46 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable SAE (any grade)detailed results MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
1.22 [0.77 ; 1.94 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable STRAE (any grade)detailed results MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
0.38 [0.18 ; 0.77 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable TRAE (any grade)detailed results MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
0.21 [0.12 ; 0.38 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable TRAE (grade 3-4)detailed results MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
0.36 [0.22 ; 0.61 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable TRAE leading to death (grade 5)detailed results MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
0.95 [0.06 ; 15.32 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable TRAE leading to discontinuation (any grade)detailed results MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
0.47 [0.21 ; 1.04 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-14 00:22 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 171
- treatments: 374,1073
